Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABLYSINOL vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Empiric therapy for presumed fungal infection in febrile neutropenic patients,Treatment of systemic fungal infections (e.g., aspergillosis, candidiasis, cryptococcosis),Treatment of visceral leishmaniasis
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; prolonged to 12–24 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Ivermectin is metabolized primarily by CYP3A4 to hydroxylated and demethylated metabolites. Phase II glucuronidation may occur. No active metabolites are identified.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; the remaining 10% is metabolized.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 85% bound to serum albumin and alpha-1-acid glycoprotein.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Volume of distribution is 0.5 L/kg, indicating distribution primarily into extracellular fluid.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral bioavailability is 40–50% due to first-pass metabolism; intramuscular bioavailability is 80%.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
GFR ≥30 m L/min: no adjustment; GFR <30 m L/min: not recommended.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Not approved for use in pediatric patients.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
No specific dose adjustment; monitor for increased sensitivity and renal function.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
This drug should be used primarily for treatment of progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of disease (e.g., oral thrush, vaginal candidiasis).
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Monitor renal function closely; may cause dose-dependent nephrotoxicity. Premedicate for infusion reactions (fever, chills, rigors). Monitor electrolytes (hypokalemia, hypomagnesemia). Risk of cardiotoxicity with rapid infusion. Use caution in patients with renal impairment; dose adjustment required.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to amphotericin B or any component of the formulation, unless the benefit outweighs the risk.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Avoid grapefruit and grapefruit juice as they may increase fingolimod concentrations. No specific dietary restrictions, but maintain adequate hydration.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, premature closure of ductus arteriosus, and neonatal renal impairment.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Contraindicated. Excreted in human milk; M/P ratio not determined. Potential for serious adverse reactions in breastfed infants.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Increased renal clearance in pregnancy may require dose increments of 30-50% to maintain therapeutic levels; monitor serum lithium concentrations and adjust dose to therapeutic range (0.6-1.2 m Eq/L).
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
ABLYSINOL (fingolimod) is a sphingosine-1-phosphate receptor modulator used for relapsing forms of multiple sclerosis. First-dose monitoring for bradycardia (6 hours) is mandatory; consider pre-treatment ECG. Avoid live vaccines during and for 2 months after therapy. Monitor for macular edema (ophthalmologic exam at baseline and 3-4 months). Lymphopenia is expected; check CBC before initiation and periodically. Drug interactions: QTc-prolonging agents, immunosuppressants, beta-blockers, calcium channel blockers. Do not use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Stay hydrated and avoid grapefruit juice; it may increase drug levels.,Report any vision changes, slow heartbeat, or dizziness immediately.,Avoid pregnancy; use effective contraception during and for 2 months after stopping.,Do not receive live vaccinations during treatment.,Take exactly as prescribed; do not skip doses or stop suddenly.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABLYSINOL vs ACTIQ, answered by our medical review team.
ABLYSINOL is a Calcineurin inhibitor that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABLYSINOL and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABLYSINOL is: Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABLYSINOL and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABLYSINOL is classified as Category C. Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, p. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.